Like other tumour suppressors, FOXO3 is frequently downregulated or inactivated in different cancers and particularly, in drug-resistant cells, usually by deregulated hyperactive PI3K-AKT signalling (Ho et al., 2008; Wang et al., 2013). Here, FOXO3 is linked to neoplasm.